Cellectar Biosciences, Inc. · NASDAQ:CLRB
Cellectar Biosciences — Investor Presentation (August 2015)
23 slides from Cellectar Biosciences's investor presentation, August 2015
Slide 1: Cellectar Biosciences
Cellectar Biosciences NASDAQ: CLRB August 2015 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This slide presenta@on contains forward-‐looking statements. Such statements are valid only as of today, and we disclaim any obliga@on to update this informa@on. These statements are only es@mates and predic@ons and are subject to known and unknown risks and uncertain@es that
Slide 3: Investment Overview
Investment Overview • Oncology-‐focused biopharmaceu@cal company in Madison, WI • First and best-‐in-‐class PDC delivery pla^orm – Phospholipid ether-‐Drug Conjugate (PDC) – Cancer-‐targe@ng delivery of oncologic payloads • Pipeline of cancer therapeu@cs and diagnos@cs • New leadership deliveri
Slide 4: PDC Product Development Pipeline
PDC Product Development Pipeline PDC Product Candidates Class Cancer TherapeuAcs Cancer DiagnosAcs Status Phase 1 Pre-‐Clinical Pre-‐Clinical Phase 2 Phase 1 PDC CLR 131 CLR 1601-‐PTX CLR 1605-‐GEM CLR 124 CLR 1502 Radioisotope Fluorophore Payload Radiotherapy Chemotherapy Chemotherapy PET/CT Im
Slide 5: Phospholipid Ether Cancer Targeting Vehicle
Phospholipid Ether Cancer TargeAng Vehicle • Proprietary small-‐molecule • Highly selec@ve cancer and CSC targe@ng • Uptake and prolonged reten@on in malignant cells – POC in broad range of cancers 6/2014 • Ability to aPach diverse oncologic payloads • Extensive research and peer reviewed scien@fic
Slide 6: PDC Delivery Platform Overview
PDC Delivery PlaIorm Overview Proprietary Small-‐Molecule, Cancer-‐TargeAng Delivery Vehicle Phospholipid Ether + Linker + Drug = PDC Linker Drug Cancer SelecAve VersaAle Chemistry Payload Diversity Increased TherapeuAc Window Enabling Targeted Delivery of Diverse Oncologic Payloads 6
Slide 7: PDC Cancer Targeting Validation in Broad Range of Cancers
PDC Cancer TargeAng ValidaAon in Broad Range of Cancers In Vitro MechanisAc POC Malignant vs normal Prostate Glioma stem cells MulAple Myeloma • Uptake Via Lipid RaWs • Cytoplasm & Cell Organelle Uptake • Prolonged RetenAon In Vivo POC • 60+ Cancer & CSC Models • TherapeuAcs & Imaging Colorectal xen
Slide 8: PDC Diverse Payload Delivery Validation
PDC Diverse Payload Delivery ValidaAon Radioisotopes for Cancer Therapy • CLR 131: Mul@ple Myeloma • Iodine-‐125 Radioisotopes for Cancer Imaging • CLR 124: Glioma • Iodine-‐123 Fluorophores for Imaging-‐Guided Surgery • CLR 1502 (near-‐infrared spectrum) • CLR 1501 (visible spectrum) Cytotoxins
Slide 9: PDC Cancer Targeting & Payload Delivery
PDC Cancer TargeAng & Payload Delivery Phospholipid Ether-‐Drug Conjugates AnAbody-‐Drug Conjugates (PDCs) (ADCs) AnAbody Extracellular Space AnAgen (+/-‐) AnAgen Lipid raWs Lipid raWs Intracellular (Cytoplasm) TargeAng: Lipid rahs TargeAng: Tumor-‐specific an@gens Delivery: Cell cytoplasm Delive
Slide 10: PDC Delivery Platform Summary
PDC Delivery PlaIorm Summary DELIVERY VEHICLE PDC ADC DescripAon PLE: Small-‐Molecule An@body: Biologic Manufacturing Cost/ Low High Complexity Cancer TargeAng Cancer Selec@ve An@gen Selec@ve -‐-‐Cancer Stem Cell Yes ? -‐-‐ Brain Metastases Yes ? Cancer Cell Uptake Membrane -‐ Cytoplasm An@gen
Slide 11: CLR 131: Lead PDC Radiotherapeutic Product
CLR 131: Lead PDC RadiotherapeuAc Product • Payload: Iodine 131 – Cytotoxic radioisotope – Thyroid cancer • PDC: CLR 131 – Targeted cytotoxic delivery 131I – Tumor uptake, reten@on and Linker efficacy demonstrated in vivo • Liquid and solid tumors – Solid tumor MTD established and ac@vity observed – I
Slide 12: Market Opportunity in Multiple Myeloma
Market Opportunity in MulAple Myeloma • Incurable hematologic cancer-‐ malignant plasma cells • Unmet need in relapse/refractory selng • 2nd most common hematologic cancer – Prevalence ~ 90,000 – Incidence ~ 26,850 – Relapse/Refractory ~ 13,000 • Global MM drug market – 2014-‐2019 8.5% CAGR • Prem
Slide 13: CLR 131: Rationale for Multiple Myeloma
CLR 131: RaAonale for MulAple Myeloma • Novel mechanism of ac@on • Single dose treatment • Established radiosensi@vity • In vivo MM cell uptake • Quan@ta@ve response criteria – M-‐protein marker • Regulatory Pathway – Unmet need in relapse/refractory pa@ents – Orphan designa@on granted – Poten@al f
Slide 14: Phase 1 Study in Multiple Myeloma Underway
Phase 1 Study in MulAple Myeloma Underway • Mul@-‐center, open label, dose escala@on trial ini@ated Q2 2015 – Determine Phase II dose • 3rd line relapse/refractory pa@ents • Primary objec@ve: Dose limi@ng toxicity • Secondary objec@ve: Efficacy • Next Steps – Evaluate cohort 1-‐ 1H 2016 – Ini@ate co
Slide 15: PDC Chemotherapeutic Program Overview
PDC ChemotherapeuAc Program Overview • Objec@ve – Develop chemotherapy PDCs with improved efficacy & tolerability • Clinical Ra@onale – Numerous chemotherapeu@cs available for PDC – Highly effec@ve yet highly toxic drugs – Improve drug therapeu@c index through targeted delivery • Business Ra@onale – Ma
Slide 16: CLR 1601-PTX: Pre-Clinical PDC Chemotherapeutic Product
CLR 1601-‐PTX: Pre-‐Clinical PDC ChemotherapeuAc Product • Payload: Paclitaxel – Well characterized chemotherapeu@c – Breast, lung and ovarian cancers • PDC: CLR 1601-‐PTX – Mul@ple deriva@ves developed – Established linker and Conjuga@on Linker PTX – In vitro studies document: • Stability • Rete
Slide 17: CLR 1502: Phase I PDC Cancer Diagnostic Product
CLR 1502: Phase I PDC Cancer DiagnosAc Product • Payload: Fluorophore – Fluorescent dye: Assess @ssue perfusion • PDC: CLR 1502 – Cancer surgery imaging agent – Accurate visualiza@on of tumor margins • Breast Cancer/Lumpectomy – Complete malignant @ssue removal – Improved pa@ent outcomes & QOL – Lim
Slide 18: CLR 124: Phase II PDC Cancer Diagnostic Product
CLR 124: Phase II PDC Cancer DiagnosAc Product • Payload: Iodine 124 – PET/CT imaging isotope – Limited cancer use • PDC: CLR 124 – More precise cancer imaging diagnos@c – Early detec@on, staging, monitoring – Prostate, colorectal, head & neck, other – Brain cancer, glioma & metastases • Next Steps
Slide 19: Intellectual Property Portfolio
Intellectual Property PorIolio Patent ComposiAon of Methods of Freedom to Methods of Use Asset Mafer Manufacturing Operate 2025 12/2016 -‐Cancer, Solid Tumors CLR 131 Orphan Drug-‐ 2028 2030 Mul@ple Myeloma -‐ Cancer Stem Cell 12/2016 2025 CLR 124 Orphan Drug-‐ 2028 -‐Cancer TRX Glioma CLR 1502
Slide 20: Near Term Milestones
Near Term Milestones Near Term Q4 Q1 Q2 PDC Product Candidate IndicaAons Milestone 2015 2016 2016 CANCER THERAPEUTICS Cohort 1 Data RR Mul@ple CLR 131 & Myeloma Ini@ate Cohort 2 Pre-‐Clinical Data CLR 1601-‐PTX Breast & Lung Update Pre-‐Clinical Data CLR 1605-‐GEM Pancrea@c, Other Update CANCER
Slide 21: Summary Financial Outlook
Summary Financial Outlook Capitaliza@on Common Stock Outstanding 7,562,762 Warrants (exercisable: $3.75-‐$25.00) 6,604,096 Op@ons 839,936 Fully Diluted 15,006,794 $4.8 M cash at June 30, 2015 21
Slide 22: Company Leadership
Company Leadership Management Board of Directors HIP Innova@on Technology-‐ EVP & Paul L. Berns Anacor Pharmaceu@cals-‐ President and Jim Caruso COO; Allos Therapeu@cs-‐ EVP & COO; Chairman of the Board of CEO; Allos Therapeu@cs-‐ President and President, CEO and Director BCI, Novar@s, BASF, BMS
Slide 23: Investment Overview
Investment Overview • Oncology-‐focused biopharmaceu@cal company in Madison, WI • First and best-‐in-‐class PDC delivery pla^orm – Phospholipid ether Drug Conjugate (PDC) – Cancer-‐targe@ng delivery of oncologic payloads • Pipeline of cancer therapeu@cs and diagnos@cs • New leadership delivering
Cellectar Biosciences — Investor Presentation (August 2015) on 6ix